natgillin/translations-raw huggingface dataset:
The following treatment-related adverse reactions were reported in adults in clinical trials or through post-marketing surveillance in patients treated with peginterferon alfa-2b, including ViraferonPeg monotherapy or ViraferonPeg/ribavirin.
Med zdravljenjem so v času kliničnih preizkušanj ali v obdobju spremljanja zdravila na trgu pri odraslih bolnikih zdravljenih s peginterferonom alfa-2b, vključno z monoterapijo z zdravilom ViraferonPeg ali s kombinirano terapijo z zdravilom ViraferonPeg in ribavirinom poročali o naslednjih neželenih učinkih, povezanih z zdravljenjem.
Injection site erythema, fatigue, pyrexia, rigors, influenza-like illness, asthenia, pain, malaise, irritability
eritem na mestu injiciranja, utrujenost, zvišana telesna temperatura, okorelost, gripi podobna bolezen, astenija, bolečine, bolehnost, razdražljivost
Volume of ViraferonPe g to administer (ml)
Volumen zdravila ViraferonPe g za uporabo (ml)
Total daily ribavirin dose (mg)
Skupni dnevni odmerek ribavirina (mg)
ViraferonPeg 100 micrograms powder and solvent for solution for injection EU/1/00/132/011
ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje EU/1/00/132/011
Powder: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate; sucrose and polysorbate 80.
Prašek: natrijev hidrogenfosfat, brezvodni; natrijev dihidrogenfosfat dihidrat, saharoza in polisorbat 80
ViraferonPeg 50 micrograms powder and solvent for solution for injection EU/1/00/132/001
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje EU/1/00/132/001
• Remove the pre-filled pen from the carton.
• Napolnjeni injekcijski peresnik vzemite iz škatle.
ViraferonPeg 50 micrograms - vial of powder
ViraferonPeg 50 mikrogramov - viala praška
Pulmonary fibrosis, pulmonary arterial hypertension Gastrointestinal disorders Very common:
pljučna fibroza, pljučna arterijska hipertenzija
Amenorrhoea, breast pain, menorrhagia, menstrual disorder, ovarian disorder, vaginal disorder, sexual dysfunction, prostatitis, erectile dysfunction
amenoreja, bolečine v dojkah, menoragija, menstrualne motnje, bolezni jajčnikov, bolezni vagine, spolne motnje, prostatitis, motnje erekcije Splošne težave in spremembe na mestu aplikacije Zelo pogosti:
ViraferonPeg is injected subcutaneously after reconstituting the powder as instructed, attaching a needle and setting the prescribed dose.
Po rekonstituciji praška v skladu z navodili, postavitvi igle na peresnik in nastavitvi predpisanega odmerka se zdravilo ViraferonPeg injicira subkutano.
ViraferonPeg 50 micrograms powder and solvent for solution for injection in pre-filled pen ViraferonPeg 80 micrograms powder and solvent for solution for injection in pre-filled pen ViraferonPeg 100 micrograms powder and solvent for solution for injection in pre-filled pen ViraferonPeg 120 micrograms powder and solvent for solution for injection in pre-filled pen ViraferonPeg 150 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku peginterferon alfa-2b
ViraferonPeg 100 micrograms - vial of powder
ViraferonPeg 100 mikrogramov - viala praška
Dental and periodontal disorders, which may lead to loss of teeth, have been reported in patients receiving ViraferonPeg and ribavirin combination therapy.
Pri bolnikih, ki so prejemali zdravilo ViraferonPeg z ribavirinom v kombinirani terapiji, so poročali o boleznih zob in obzobnega tkiva, ki lahko vodijo do izgube zob.
The reconstituted solution has a concentration of 120 micrograms/0.5 ml.
Koncentracija rekonstituirane raztopine je 120 mikrogramov/0,5 ml.
How to store ViraferonPeg
Shranjevanje zdravila ViraferonPeg
ViraferonPe g strength (g/0.5 ml)
Jakost zdravila ViraferonPe g (µg/0,5 ml)
The following treatment-related adverse reactions were reported in the study in children and adolescent patients treated with ViraferonPeg in combination with ribavirin.
V študiji pri otrocih in mladostnikih, zdravljenih z zdravilom ViraferonPeg v kombinaciji z ribavirinom, so poročali o naslednjih z zdravljenjem povezanih neželenih učinkih.
ViraferonPeg 50 micrograms powder and solvent for solution for injection ViraferonPeg 80 micrograms powder and solvent for solution for injection ViraferonPeg 100 micrograms powder and solvent for solution for injection ViraferonPeg 120 micrograms powder and solvent for solution for injection ViraferonPeg 150 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
Autoimmune disease
Avtoimune bolezni
Avoid your belly button (navel) and waistline.
Izognite se popku in predelu okrog pasu.
ViraferonPeg 50 micrograms powder and solvent for solution for injection ViraferonPeg 80 micrograms powder and solvent for solution for injection ViraferonPeg 100 micrograms powder and solvent for solution for injection ViraferonPeg 120 micrograms powder and solvent for solution for injection ViraferonPeg 150 micrograms powder and solvent for solution for injection
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje
You or your partner must use an effective birth control during the time you are taking ribavirin and for 7 months after stopping treatment.
V času jemanja ribavirina in še 7 mesecev po zaključku zdravljenja morate vi ali vaša partnerka uporabljati učinkovito kontracepcijo.
The reconstituted solution has a concentration of 150 micrograms/0.5 ml.
Koncentracija rekonstituirane raztopine je 150 mikrogramov/0,5 ml.
The reconstituted solution has a concentration of 120 micrograms in 0.5 ml.
Koncentracija rekonstituirane raztopine je 120 mikrogramov na 0,5 ml.
The reconstituted solution has a concentration of 80 micrograms/0.5 ml.
Koncentracija rekonstituirane raztopine je 80 mikrogramov/0,5 ml.
Liver enzymes and hepatic function should be closely monitored in cirrhotic patients.
Pri bolnikih s cirozo morate natančno spremljati jetrne encime in delovanje jeter.
One vial of powder contains 80 micrograms of peginterferon alfa-2b and provides 80 micrograms/0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
Ena viala praška vsebuje 80 mikrogramov peginterferona alfa-2b in ima 80 mikrogramov/0,5 ml peginterferona alfa-2b po rekonstituciji v skladu s priporočili.
ViraferonPeg is supplied as: - 1 vial of powder for solution for injection and 1 ampoule of solvent for parenteral use; - 1 vial of powder for solution for injection, 1 ampoule of solvent for parenteral use, 1 injection syringe, 2 injection needles and 1 cleansing swab; - 4 vials of powder for solution for injection and 4 ampoules of solvent for parenteral use;
ViraferonPeg je na voljo v naslednjih pakiranjih: - 1 viala s praškom za raztopino za injiciranje in 1 ampula z vehiklom za parenteralno uporabo, - 1 viala s praškom za raztopino za injiciranje, 1 ampula z vehiklom za parenteralno uporabo, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon, - 4 viale s praškom za raztopino za injiciranje in 4 ampule z vehiklom za parenteralno uporabo, - 4 viale s praškom za raztopino za injiciranje, 4 ampule z vehiklom za parenteralno uporabo, 4 injekcijske brizge, 8 injekcijskih igel in 4 čistilni tamponi, - 6 vial s praškom za raztopino za injiciranje in 6 ampul z vehiklom za parenteralno uporabo, - 12 vial s praškom za raztopino za injiciranje, 12 ampul z vehiklom za parenteralno uporabo, 12 injekcijskih brizg, 24 injekcijskih igel in 12 čistilnih tamponov.
The reconstituted solution has a concentration of 150 micrograms in 0.5 ml.
Koncentracija rekonstituirane raztopine je 150 mikrogramov na 0,5 ml.
What ViraferonPeg contains
Kaj vsebuje zdravilo ViraferonPeg
Disodium phosphate, anhydrous Sodium dihydrogen phosphate dihydrate Sucrose
Prašek natrijev hidrogenfosfat, brezvodni natrijev dihidrogenfosfat dihidrat saharoza polisorbat 80
The reconstituted solution has a concentration of 80 micrograms in 0.5 ml.
Koncentracija rekonstituirane raztopine je 80 mikrogramov na 0,5 ml.
Minimum delivery for pen is 0.2 ml.
Minimalni volumen za injiciranje pri peresniku je 0,2 ml. * Obvezna uporaba viale.
EU/1/00/132/008 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/009 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
EU/1/00/132/008 (4 viale praška, 4 ampule vehikla) EU/1/00/132/009 (4 viale praška, 4 ampule vehikla, 4 injekcijske brizge, 8 injekcijskih igel, 4 čistilni tamponi)
The plasma half-life of ViraferonPeg is prolonged compared with nonpegylated interferon alfa-2b.
V primerjavi z nepegiliranim interferonom alfa-2b je njegova razpolovna doba v plazmi daljša.
One vial of powder contains 120 micrograms of peginterferon alfa-2b and provides 120 micrograms/0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
Ena viala praška vsebuje 120 mikrogramov peginterferona alfa-2b in ima 120 mikrogramov/0,5 ml peginterferona alfa-2b po rekonstituciji v skladu s priporočili.
ViraferonPeg 80 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje Eno vialo se rekonstituira z 0,7 ml vode za injekcije za dajanje do 0,5 ml raztopine.
The reconstituted solution has a concentration of 100 micrograms/0.5 ml.
Koncentracija rekonstituirane raztopine je 100 mikrogramov/0,5 ml.
nd dose reduction of ribavirin is to 8 mg/kg/day.
Pri otrocih in mladostnikih je prvo zmanjšanje odmerka ribavirina na 12 mg/kg/dan, drugo zmanjšanje odmerka ribavirina pa na 8 mg/kg/dan.
Also see SmPCs for ribavirin and boceprevir if ViraferonPeg is to be administered in combination therapy in patients with chronic hepatitis C.
Pri uporabi zdravila ViraferonPeg v kombinirani terapiji pri bolnikih s kroničnim hepatitisom C glejte tudi SmPC za ribavirin in boceprevir.
Pen label - ViraferonPeg 150 micrograms powder and solvent for solution for injection in prefilled pen
Nalepka na peresniku - ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
Desipramine (CYP2D6 substrate)
navedba smiselno ni potrebna dezipramin (substrat CYP2D6)
12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs
12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov 100 mikrogramov/0,5 ml
Pen label - ViraferonPeg 120 micrograms powder and solvent for solution for injection in prefilled pen
Nalepka na peresniku - ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
Common side effects (may affect up to 1 in 10 people): - fungal infection, common cold, cold sores, pharyngitis (sore throat), sinusitis, ear infection, coughing, throat pain, feeling cold, eye pain, - decrease in blood clotting cells called platelets, that may result in easy bruising and spontaneous bleeding, swollen glands (swollen lymph nodes), blood thyroid tests abnormalities, decrease in thyroid gland activity, which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms,
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - glivične okužbe, navaden prehlad, herpesni izpuščaji, faringitis (vnetje grla), sinusitis, okužba ušes, kašelj, bolečine v grlu, občutek mrazenja, očesne bolečine, - zmanjšanje števila celic za strjevanje krvi, ki jim pravimo trombociti, kar lahko vodi do nagnjenosti k nastanku podplutb in spontanih krvavitev, otekle žleze (otekle bezgavke),
Headache, dizziness
glavobol, omotica
nd dose reduction of ViraferonPeg is to 0.5 µg/kg/week.
Če je potrebno, lahko še drugič zmanjšate odmerek zdravila ViraferonPeg, in sicer na 0,5 µg/kg/teden.
Weight decreased
Odpoved jeter
ViraferonPeg monotherapy - Adults
Monoterapija z zdravilom ViraferonPeg - odrasli bolniki Odmerek za injiciranje
Carton 50 micrograms powder and solvent for solution for injection in pre-filled pen
Škatla 50 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
EU/1/00/132/003 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/004 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
EU/1/00/132/003 (4 viale praška, 4 ampule vehikla) EU/1/00/132/004 (4 viale praška, 4 ampule vehikla, 4 injekcijske brizge, 8 injekcijskih igel, 4 čistilni tamponi)
You may hear clicking sounds as you dial.
Med obračanjem gumba boste morda slišali klikanje.
The reconstituted solution has a concentration of 50 micrograms/0.5 ml.
Koncentracija rekonstituirane raztopine je 50 mikrogramov/0,5 ml.
Co-administered Medicine
Sočasno uporabljena zdravila
The reconstituted solution has a concentration of 100 micrograms in 0.5 ml.
Koncentracija rekonstituirane raztopine je 100 mikrogramov na 0,5 ml.
Carton 150 micrograms powder and solvent for solution for injection in pre-filled pen
Škatla 150 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
One vial of powder contains 50 micrograms of peginterferon alfa-2b and provides 50 micrograms/0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
Ena viala praška vsebuje 50 mikrogramov peginterferona alfa-2b in ima 50 mikrogramov/0,5 ml peginterferona alfa-2b po rekonstituciji v skladu s priporočili.
ViraferonPeg 150 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje Eno vialo se rekonstituira z 0,7 ml vode za injekcije za dajanje do 0,5 ml raztopine.
Carton 120 micrograms powder and solvent for solution for injection in pre-filled pen
Škatla 120 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
One vial of powder contains 150 micrograms of peginterferon alfa-2b and provides 150 micrograms/0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
Ena viala praška vsebuje 150 mikrogramov peginterferona alfa-2b in ima 150 mikrogramov/0,5 ml peginterferona alfa-2b po rekonstituciji v skladu s priporočili.
At the end of 24 weeks post-treatment follow-up, mean decrease from baseline in weight and height percentiles were still of 3 percentiles and 7 percentiles respectively, and 20 % of the children continued to have inhibited growth (growth velocity < 3
Na koncu 24 tednov spremljanja bolnikov po zaključku zdravljenja, je bilo povprečno zmanjšanje percentilov telesne mase in telesne višine glede na začetne vrednosti še vedno 3 percentile oz. 7 percentilov.
nd dose reduction of ViraferonPeg is to 20 g/m 2/week.
Najmanjša jakost zdravila ViraferonPeg je 50 g/0,5 ml.
Pen label - ViraferonPeg 50 micrograms powder and solvent for solution for injection in prefilled pen
Nalepka na peresniku - ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
The pharmacokinetics of ViraferonPeg have not been evaluated in patients with severe hepatic dysfunction.
Okvara jeter Pri bolnikih s hudo jetrno okvaro farmakokinetike zdravila ViraferonPeg niso ocenjevali.
ViraferonPeg is supplied as: - 1 pre-filled pen (CLEARCLICK) containing powder and solvent for solution for injection, 1 needle ("Push-On Needle"), 2 cleansing swabs; - 4 pre-filled pens (CLEARCLICK) containing powder and solvent for solution for injection, 4 needles ("Push-On Needle"),
Zdravilo ViraferonPeg je na voljo v naslednjih pakiranjih: - 1 napolnjen injekcijski peresnik (CLEARCLICK) s praškom in vehiklom za raztopino za injiciranje, 1 igla ("Igla na potisk"), 2 čistilna tampona; - 4 napolnjeni injekcijski peresniki (CLEARCLICK) s praškom in vehiklom za raztopino za injiciranje, 4 igle ("Igla na potisk"), 8 čistilnih tamponov; - 12 napolnjenih injekcijskih peresnikov (CLEARCLICK) s praškom in vehiklom za raztopino za injiciranje, 12 igel ("Igla na potisk"), 24 čistilnih tamponov.
One vial of powder contains 100 micrograms of peginterferon alfa-2b and provides 100 micrograms/0.5 ml of peginterferon alfa-2b when reconstituted as recommended.
Ena viala praška vsebuje 100 mikrogramov peginterferona alfa-2b in ima 100 mikrogramov/0,5 ml peginterferona alfa-2b po rekonstituciji v skladu s priporočili.
EU/1/00/132/011 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/012 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab)
EU/1/00/132/011 (1 viala praška, 1 ampula vehikla) EU/1/00/132/012 (1 viala praška, 1 ampula vehikla, 1 injekcijska brizga, 2 injekcijski igli, 1 čistilni tampon)
Carton 80 micrograms powder and solvent for solution for injection in pre-filled pen
Škatla 80 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
ViraferonPeg 120 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje Eno vialo se rekonstituira z 0,7 ml vode za injekcije za dajanje do 0,5 ml raztopine.
Do not pass it on to others.
Ne injicirajte na to mesto.
ViraferonPeg 80 micrograms powder for injection peginterferon alfa-2b
ViraferonPeg 80 mikrogramov prašek za injekcijo peginterferon alfa-2b s.c.
Ear pain
bolečine v ušesu
ViraferonPeg 150 micrograms powder and solvent for solution for injection Each vial contains 150 micrograms of peginterferon alfa-2b measured on a protein basis.
ViraferonPeg 150 mikrogramov prašek in vehikel za raztopino za injiciranje Ena viala vsebuje 150 mikrogramov peginterferona alfa-2b, merjeno na proteinski osnovi.
ANNEX TO THE PACKAGE LEAFLET
PRILOGA NAVODILU ZA UPORABO
• Hold the pre-filled pen upright with the dial on the bottom.
• Napolnjeni injekcijski peresnik držite pokonci, tako da je gumb za nastavitev spodaj.
Bitherapy and monotherapy
Dvojna terapija in monoterapija
Ophthalmologic disorders, including retinal haemorrhages, retinal exudates, serous retinal detachment, and retinal artery or vein occlusion have been reported in rare instances after treatment with alpha interferons (see section 4.8).
V redkih primerih so po zdravljenju z interferoni alfa poročali o očesnih boleznih, kot so krvavitve v mrežnici, eksudati na mrežnici, serozni odstop mrežnice ter zapora mrežnične arterije ali vene (glejte poglavje 4.8).
ViraferonPeg 120 micrograms powder and solvent for solution for injection Each vial contains 120 micrograms of peginterferon alfa-2b measured on a protein basis.
ViraferonPeg 120 mikrogramov prašek in vehikel za raztopino za injiciranje Ena viala vsebuje 120 mikrogramov peginterferona alfa-2b, merjeno na proteinski osnovi.
Careful co-administration of thioridazine with the product (ViraferonPeg) is recommended.
Pri sočasni uporabi tioridazina z zdravilom ViraferonPeg je potrebna previdnost.
The reconstituted solution has a concentration of 50 micrograms in 0.5 ml.
Koncentracija rekonstituirane raztopine je 50 mikrogramov na 0,5 ml.
Pen label - ViraferonPeg 80 micrograms powder and solvent for solution for injection in prefilled pen
Nalepka na peresniku - ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
Retinal exudates
perikardni izliv
Carton 100 micrograms powder and solvent for solution for injection in pre-filled pen
Škatla 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
EU/1/00/132/047 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/048 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/050 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/047 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/1/00/132/048 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/1/00/132/050 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
ViraferonPeg 80 micrograms powder and solvent for solution for injection Each vial contains 80 micrograms of peginterferon alfa-2b measured on a protein basis.
ViraferonPeg 80 mikrogramov prašek in vehikel za raztopino za injiciranje Ena viala vsebuje 80 mikrogramov peginterferona alfa-2b, merjeno glede na beljakovine.
Plasma HCV-RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory *Intent to treat population includes 7 patients for whom at least 12 weeks of prior therapy could not be confirmed.
*ITT (Intent to treat) populacija vključuje 7 ljudi, pri katerih vsaj 12 tednov zdravljenja ni bilo mogoče potrditi.
Eye pain
bolečine v očesu
HCV/HIV Co-infected patients
Bolniki, sočasno okuženi s HCV/HIV
HCV/HIV co-infected patients
Bolniki, sočasno okuženi s HCV / HIV
ViraferonPeg 50 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
ViraferonPeg 50 mikrogramov prašek in vehikel za raztopino za injiciranje Eno vialo se rekonstituira z 0,7 ml vode za injekcije za dajanje do 0,5 ml raztopine.
ViraferonPeg 100 micrograms powder and solvent for solution for injection Each vial contains 100 micrograms of peginterferon alfa-2b measured on a protein basis.
ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje Ena viala vsebuje 100 mikrogramov peginterferona alfa-2b, merjeno na proteinski osnovi.
EU/1/00/132/016 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/017 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab)
EU/1/00/132/016 (1 viala praška, 1 ampula vehikla) EU/1/00/132/017 (1 viala praška, 1 ampula vehikla, 1 injekcijska brizga, 2 injekcijski igli, 1 čistilni tampon)
ViraferonPeg 120 micrograms powder for injection peginterferon alfa-2b
ViraferonPeg 120 mikrogramov prašek za injekcijo peginterferon alfa-2b s.c.
ViraferonPeg 100 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
ViraferonPeg 100 mikrogramov prašek in vehikel za raztopino za injiciranje Eno vialo se rekonstituira z 0,7 ml vode za injekcije za dajanje do 0,5 ml raztopine.
EU/1/00/132/035 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/036 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/038 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/035 (1 peresnik, 1 injekcijska igla in 2 čistilna tampona) EU/1/00/132/036 (4 peresniki, 4 injekcijske igle in 8 čistilnih tamponov) EU/1/00/132/038 (12 peresnikov, 12 injekcijskih igel in 24 čistilnih tamponov)
Metabolism of thioridazine is suppressed by inhibitory action of the product (ViraferonPeg) on CYP2D6.
Zaviralni učinek zdravila ViraferonPeg na CYP2D6 upočasni presnovo tioridazina.
ViraferonPeg 50 micrograms powder for injection peginterferon alfa-2b
ViraferonPeg 50 mikrogramov prašek za injekcijo peginterferon alfa-2b s.c.